Long-term continuation of levetiracetam in patients with refractory epilepsy
- 26 June 2001
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 56 (12) , 1772-1774
- https://doi.org/10.1212/wnl.56.12.1772
Abstract
The long-term continuation (retention) rate, efficacy, and safety data of the new antiepileptic drug levetiracetam (LEV) was evaluated in all patients with epilepsy exposed to the drug during its developmental program (n = 1,422). The retention rate was estimated to be 60% after 1 year and 32% after 5 years. Thirty-nine percent (512/1,325) of patients had a seizure reduction of ≥50%, and 13% (183/1,422) became seizure-free for at least 6 months. LEV seems an effective and well tolerated new antiepileptic drug.Keywords
This publication has 10 references indexed in Scilit:
- Levetiracetam for partial seizuresNeurology, 2000
- Revisiting the Concept of Identifiable NeuronsBrain, Behavior and Evolution, 2000
- Prognostic Factors Affecting Long‐Term Retention of Topiramate in Patients with Chronic EpilepsyEpilepsia, 2000
- Pharmacokinetic profile of levetiracetamPharmacology & Therapeutics, 2000
- The Long‐Term Use of Gabapentin, Lamotrigine, and Vigabatrin in Patients with Chronic EpilepsyEpilepsia, 1999
- Topiramate in clinical practice: first year's postlicensing experience in a specialist epilepsy clinicJournal of Neurology, Neurosurgery & Psychiatry, 1999
- Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsyPublished by Elsevier ,1998
- The New Antiepileptic Drugs: A Systematic Review of Their Efficacy and TolerabilityEpilepsia, 1997
- Difficulties in extrapolating from clinical trial data to clinical practice: The case of antiepileptic drugsNeurology, 1997
- The impact of new antiepileptic drugs on the prognosis of epilepsyNeurology, 1996